 LEIDEN, Netherlands CAMBRIDGE, Mass., Sept. 08, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR ProQR, today announced a global licensing and research collaboration with Eli Lilly and Company Lilly focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQRs proprietary Axiomer RNA editing platform to progress new drug targets toward clinical development and commercialization. 